# Fibroblast Growth Factor-23 (FGF-23) is Independently Associated With Left Ventricular Mass Index (LVMI) and Myocardial Performance Index (MPI) in Haemodialysis Patients

> **NCT01154842** · — · UNKNOWN · sponsor: **Diskapi Teaching and Research Hospital** · enrollment: 128 (actual)

## Conditions studied

- Fibroblast

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01154842
- **Lead sponsor:** Diskapi Teaching and Research Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-12
- **Primary completion:** 2010-05
- **Final completion:** 2010-06
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2010-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01154842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01154842, "Fibroblast Growth Factor-23 (FGF-23) is Independently Associated With Left Ventricular Mass Index (LVMI) and Myocardial Performance Index (MPI) in Haemodialysis Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01154842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*